Expanding the number of validated iPSC-derived cardiomyocytes for safety pharmacology studies

2021 ◽  
Vol 111 ◽  
pp. 107030
Author(s):  
Annie Armstrong ◽  
Sarah Himmerich ◽  
Megan K. Livingston ◽  
Coby B. Carlson ◽  
Cara R. Rieger ◽  
...  
Keyword(s):  
2020 ◽  
Vol 4 ◽  
pp. 239784732097863
Author(s):  
Stanley E Lazic ◽  
Dominic P Williams

Predicting the safety of a drug from preclinical data is a major challenge in drug discovery, and progressing an unsafe compound into the clinic puts patients at risk and wastes resources. In drug safety pharmacology and related fields, methods and analytical decisions known to provide poor predictions are common and include creating arbitrary thresholds, binning continuous values, giving all assays equal weight, and multiple reuse of information. In addition, the metrics used to evaluate models often omit important criteria and models’ performance on new data are often not assessed rigorously. Prediction models with these problems are unlikely to perform well, and published models suffer from many of these issues. We describe these problems in detail, demonstrate their negative consequences, and propose simple solutions that are standard in other disciplines where predictive modelling is used.


2010 ◽  
Vol 62 (2) ◽  
pp. e4
Author(s):  
Pierre Laine ◽  
Mark Deurink ◽  
Alan Bass ◽  
Jonathan Bright ◽  
Richard Briscoe ◽  
...  
Keyword(s):  

2013 ◽  
Vol 68 (1) ◽  
pp. e50
Author(s):  
Clarisse Duval ◽  
Martine Lemaire ◽  
Philippe Guillaume ◽  
Daniel Provost ◽  
Guillaume Froget

2007 ◽  
Vol 56 (2) ◽  
pp. e24
Author(s):  
Nick Dürmüller ◽  
Pierre Lacroix ◽  
Roger D. Porsolt ◽  
Paul Moser
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document